Fundz

Bilayer Therapeutics, Inc. reported raising $2 Million in an initial SEC Form D filing, from an offering of $3.6 Million

PRIVATEApr 29, 2021$2M of $3.6M raised

Amount Raised

$2 Million

$2 Million sold, per SEC Form D (first sale Apr 29, 2021)

Round Type

Seed

CambridgeBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as Bilayer Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Myra Vision raised $15M on June 11, 2021.
  • binx health Ltd raised $104M on June 11, 2021.
  • Kineta, Inc. raised $10M on June 11, 2021.
  • Surface Ophthalmics, Inc. raised $5.8M on June 10, 2021.
  • Owl Peak Technologies raised an undisclosed amount (Seed) on June 10, 2021.
  • Onchilles Pharma raised an undisclosed amount (Series A) on June 10, 2021.

Who to call at Bilayer Therapeutics, Inc., and when

A new round usually means Bilayer Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Bilayer Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Bilayer Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Bilayer Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Bilayer Therapeutics, Inc.

Location

ONE BROADWAY, 14TH FLOOR

Cambridge, Massachusetts, United States

About

Bilayer Therapeutics is a development-stage company founded by a team of world-renowned drug development and delivery experts and gastroenterologists. Its technology stimulates the body’s innate mechanisms for regulating metabolism and motility by targeting the receptor TGR5 and by increasing native incretin levels such as GLP-1. It achieves these effects by delivering the naturally occurring bile acid chenodeoxycholate via a proprietary bilayer tablet technology. The company is developing innovative first-in-class treatments for a range of metabolic and motility disorders, initially for metabolic disorder (obesity, diabetes) with its drug candidate BL-050 and for motility disorders such as chronic constipation with its drug candidate BL-010.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Bilayer Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsThomas C., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Bilayer Therapeutics, Inc.'s next move

See what Strategic adds

Bilayer Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.